Menu

Contributors

Meet some of the people featured in the May 2015 issue of The Scientist.

May 1, 2015
Jenny Rood

GISELLE HABERA native of Melbourne, Australia, Genevieve Martin enrolled in a one-year honors program during her medical training at Monash University to study age-related changes in monocytes from HIV-infected women. “When I started this year in HIV medicine, I just became absolutely fascinated, and I thought, this is what I want to do,” Martin says.  During her honors research, she first encountered the concept of HIV latency and was struck by “the audacity of the idea.” Martin has just begun doctoral research on the topic with John Frater at the University of Oxford.


 

JODI GIRNUNMatthew Pace’s high-school fascination with biology continued during his undergraduate years at St. Joseph’s University in his hometown of Philadelphia, where he earned extra money over the summer working in a biochemistry research lab. Eventually, Pace became interested in pathogens and disease, and focused on HIV latency during his doctoral work with Una O’Doherty at the University of Pennsylvania. “It’s much less straightforward . . . because we don’t really understand it yet,” he says of HIV latency. He is now a postdoctoral researcher in Frater’s lab at Oxford.  
 

 

JOHN FRATERWorking in the AIDS ward of St. Mary’s Hospital in London in the mid-1990s, John Frater, fresh out of medical school, decided to conduct  HIV research. He pursued doctoral work with Myra McClure at Imperial College London, investigating the responses of different HIV strains to retroviral medicines, and later probed the human immune response to the virus as a clinical lecturer in the lab of Rodney Phillips at Oxford. Frater remains at Oxford, where he is now a research lecturer in the Nuffield Department of Medicine. He is cofounder and codirector of Collaborative HIV Eradication of Reservoirs: UK Biomedical Research Centres (CHERUB), a collaboration among multiple research institutes that seeks a definitive cure for the disease.

Martin, Pace, and Frater explore the mystery of HIV latency in “Hidden Menace.”


IAVIIn the 1970s, Wayne Koff investigated antiviral drugs against influenza while a doctoral student in Vernon Knight’s lab at Baylor College of Medicine. Pursuing what would become a lifelong interest in vaccine development, Koff went on to explore dengue vaccine development and macrophage-mediated suppression of viral infections, a line of inquiry he followed as an assistant professor at the University of Texas MD Anderson Cancer Center in the mid-1980s. In 1986, as the HIV/AIDS epidemic emerged as a public health concern, he undertook a one-year internship at the National Institutes of Health to study the disease, inspiring him to combine his latest research with his long-standing interest in vaccines. After completing his internship, Koff spent four years as NIAID’s branch chief for AIDS vaccine research and development before serving six years as vice president for vaccine research and development at United Biomedical. In 1998, Koff joined the International AIDS Vaccine Initiative (IAVI) as vice president of research and development and is today IAVI’s chief scientific officer. “We’re in a renaissance period in the AIDS vaccine effort,” Koff says. “Years ago, people would ask if an AIDS vaccine would ever be possible. Now, the question is no longer ‘If.’ It’s ‘When?’ ”

Koff explains the science behind designing an HIV/AIDS vaccine in “Defeating the Virus.”


HEIDI LARSONAs a medical student at the University of Ghent in his native Belgium, Peter Piot was told there was no future in infectious disease medicine. Undaunted, he conducted doctoral research in microbiology at the Institute of Tropical Medicine Antwerp, where in 1976 he analyzed the blood sample of a Belgian nun who had died in northern Zaire (today Democratic Republic of the Congo). He and his colleagues isolated a completely new and deadly virus: Ebola. In the early 1980s, Piot began serving on the front lines of the rising HIV/AIDS epidemic in both Antwerp’s gay community and in Africa among heterosexuals. “I never understood why a virus would care about the sexual orientation of a human host,” Piot said in a 2012 interview at the London School of Hygiene and Tropical Medicine, where he has served as director since 2010. Piot’s interest in advocacy led him to found and direct UNAIDS from 1995 to 2008. Piot provides his perspective on the history and future of the science and politics of AIDS in an essay, “Attacking AIDS on Many Fronts,” based on his new book AIDS: Between Science and Politics.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Improved Accuracy in Multiplex Assays

Improved Accuracy in Multiplex Assays

Interference by endogenous antibodies in immunoassays is a well-documented phenomenon. Download this poster to learn about the profound effects that this can have on the data and how development expertise and assay design can eliminate or reduce the effects of endogenous antibodies.

Complete Pathology Solutions: Make Every Minute Count

Complete Pathology Solutions: Make Every Minute Count

From sample collection and handling, to fixation and processing, tissue staining, and covering all your IHC and water purification needs—you can have confidence in the quality of your results with MilliporeSigma's one-stop pathology solution.

Preparing Cell Or Tissue Lysates For ELISA Kits

Preparing Cell Or Tissue Lysates For ELISA Kits

RayBiotech manufactures over 2,000 high fully validated, GMP-compliant ELISA kits. In this blog post we explain how to prepare cell or tissue lysates for ELISA Kits.

Norgen Biotek Achieves Illumina Propel Certification as a Service Provider for Next Generation Sequencing

Norgen Biotek Achieves Illumina Propel Certification as a Service Provider for Next Generation Sequencing

Norgen Biotek Corp., an innovative privately held Canadian biotechnology company focusing primarily on nucleic acid and protein stabilization and purification, as well as providing high quality services to the scientific community, today announced that it has become Propel-Certified through Illumina as a Next Generation Sequencing (NGS) service provider.